The advent of oligonucleotide-based microarray platforms has facilitated the development of several clinically useful gene expression signatures, which offer the promise of incorporating genomic features other than ER, PR, and HER2 into clinical management of breast cancer patients. The gene discussed is PGR; the disease is breast carcinoma.